Sun Yat-sen University: all 1,680 studies

Page 3 of 17. Open to participants first (609), then studies with results posted, then the rest; newest registration first within each.

• Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)Not yet recruitingNCT07032532Phase 2
• Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I StudyNot yet recruitingNCT07028047Phase 1
• AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal CancerNot yet recruitingNCT07021950Phase 2
• Afterload Mismatch Predictive modLE for Transcatheter Edge-to-Edge Repair (AMPLE-TEER)RecruitingNCT07019935
• ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRCRecruitingNCT07012954Phase 1/2
• Omitting CTV for Primary Tumor in LS-SCLCRecruitingNCT07008716Phase 3
• A Multi-omics Study of BRAF V600E Mutant Colorectal CancerNot yet recruitingNCT07007689
• Effectiveness Evaluation of the "Mosquito-Free Campus" Initiative on Dengue Fever Prevention and Control: A Cluster Randomized Controlled TrialNot yet recruitingNCT07002021Not applicable
• TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical TrialNot yet recruitingNCT06987123Phase 2
• PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLCRecruitingNCT06977074Phase 2
• Safety and Efficacy of Pucotenlimab in pLECCRecruitingNCT06969534Phase 2
• Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B CarriersRecruitingNCT06966232Phase 3
• Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3ANot yet recruitingNCT06961500Phase 2
• A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)Not yet recruitingNCT06959693Phase 2/3
• Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerNot yet recruitingNCT06957561Phase 1/2
• A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT06947811Phase 1/2
• New Triple Therapy in Newly Diagnosed Type 2 DiabetesNot yet recruitingNCT06946628Phase 3
• QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaRecruitingNCT06939855Phase 2
• Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)RecruitingNCT06926959
• Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）RecruitingNCT06924398Phase 2
• A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal CancerNot yet recruitingNCT06919510Phase 2
• TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal CarcinomaRecruitingNCT06912711Phase 2
• Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06912074Phase 2
• Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.RecruitingNCT06911684Phase 2
• Probiotics in Advanced Urothelial CarcinomaRecruitingNCT06904573Phase 2
• Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ CancerNot yet recruitingNCT06904300Phase 2
• Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal CancerRecruitingNCT06903858Phase 2
• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast CancerRecruitingNCT06900647Phase 1
• PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal CarcinomaNot yet recruitingNCT06900218Phase 3
• TACE Combined Surgery for the Resectable Huge HCCRecruitingNCT06898398
• A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V MutationRecruitingNCT06898385Phase 1
• mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon CancerNot yet recruitingNCT06890624Phase 2
• Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast CancerRecruitingNCT06877416
• MItral Regurgitation Risk Assessment and CLinical modEllingRecruitingNCT06876883
• Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal CancerNot yet recruitingNCT06861712Phase 2
• Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with ChemotherapyRecruitingNCT06857292Phase 2
• A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCLRecruitingNCT06855823Phase 1/2
• Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate CancerRecruitingNCT06854250Phase 2
• GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.RecruitingNCT06851247Phase 2
• Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety StudyRecruitingNCT06848582Not applicable
• Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: a Phase II StudyRecruitingNCT06848569Phase 2
• Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaRecruitingNCT06846489Phase 2
• Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.RecruitingNCT06836505Phase 1/2
• Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRIRecruitingNCT06831357
• A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)RecruitingNCT06829147
• Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingNCT06827717Phase 2
• EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaRecruitingNCT06802835Phase 1/2
• The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration StudyRecruitingNCT06801977
• Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06793956Phase 1
• Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon CancerNot yet recruitingNCT06790212Phase 2
• Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular CarcinomaRecruitingNCT06788353
• A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTBRecruitingNCT06781151
• DYNAMICS-LYNCH：DNA Methylation Analysis in Stool for Screening of Lynch Syndrome-Associated Colorectal CancerNot yet recruitingNCT06772844
• Vunakizumab in Adults with SpondyloarthritisNot yet recruitingNCT06770088Phase 4
• Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast CancerRecruitingNCT06768931Phase 2
• Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal CancerRecruitingNCT06764680Phase 2
• UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid TumorsRecruitingNCT06760117Phase 1
• Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLRecruitingNCT06760039Phase 1/2
• Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular LymphomaNot yet recruitingNCT06757894Phase 2
• Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II TrialNot yet recruitingNCT06750952Phase 2
• QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Phase 3
• Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLRecruitingNCT06742502Phase 2
• TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular CarcinomaRecruitingNCT06740370Not applicable
• SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.Not yet recruitingNCT06739317Phase 2/3
• HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular CarcinomaRecruitingNCT06737913Phase 2
• Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer PatientsRecruitingNCT06736678Not applicable
• The Optimal Radioimmunotherapy Combinations for Advanced TNBCRecruitingNCT06735131Phase 2
• Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung CancerRecruitingNCT06734702Phase 3
• Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)RecruitingNCT06733051Phase 2
• An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With EverolimusRecruitingNCT06730672Phase 2
• Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable ThymomaRecruitingNCT06730308Phase 2
• Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung CancerRecruitingNCT06730295Phase 2
• Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)RecruitingNCT06726421Phase 3
• Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung CancerRecruitingNCT06719700Phase 2
• ScreenTalk to Improve Colorectal Cancer Screening Uptake Among First-degree Relatives of Patients: a Study ProtocolNot yet recruitingNCT06710860Not applicable
• WHO Mental Health Gap Action Program (mhGAP) for Improving Child Mental and Behavioral Disorder Service Quality in ChinaRecruitingNCT06702410Not applicable
• Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinoma Patients: a Prospective Cohort StudyNot yet recruitingNCT06695936
• A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving SurgeryRecruitingNCT06686459Not applicable
• A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)Not yet recruitingNCT06684873Phase 2
• Arsenous Acid for Refractory Triple-Negative Breast CancerRecruitingNCT06678048Phase 2
• Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.RecruitingNCT06675214Phase 3
• Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT06669611Phase 3
• A TTM-based Smoking Cessation Intervention in Helping Expectant Fathers to Quit Smoking and Maintain AbstinenceNot yet recruitingNCT06663475Not applicable
• Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
• Nomogram for Predicting Biliary ComplicationNot yet recruitingNCT06658665
• Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPCRecruitingNCT06657690Phase 2
• Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）RecruitingNCT06647940Phase 2
• High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)Not yet recruitingNCT06646211Phase 2
• Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular CarcinomaRecruitingNCT06644430
• HAIC Compared With TACE in Huge Hepatocellular CarcinomaRecruitingNCT06641713
• Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Colorectal Cancer SurgeryEnrolling by invitationNCT06636864Not applicable
• Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.RecruitingNCT06631391Phase 1
• GOS and the Management of HyperuricemiaRecruitingNCT06630377Not applicable
• Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular CarcinomaRecruitingNCT06624098Not applicable
• Liver Cancer Prognosis Investigation StudyNot yet recruitingNCT06623734
• TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicable
• Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung CancerNot yet recruitingNCT06614231Phase 2
• Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal CarcinomaRecruitingNCT06611150Phase 1
• SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and HypopharynxRecruitingNCT06611137Phase 2
• Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCCRecruitingNCT06609876Not applicable

← Sun Yat-sen University overview and focus areas